<DOC>
	<DOCNO>NCT02570399</DOCNO>
	<brief_summary>This prospective , multicentric , phase II feasibility study aim address early late side effect hypofractionated ablative radiotherapy oligometastatic patient lymph node metastasis genito-urinary , gastro-intestinal gynaecological cancer .</brief_summary>
	<brief_title>High Dose SBRT Abdominal-Pelvic Lymph Nodal Lesions Oligometastatic Patients</brief_title>
	<detailed_description>The purpose prospective , multicentric , phase II study determine feasibility Stereotactic Body Radiation Therapy stage IV select oligometastatic patient , look acute late toxicity . Investigators also want verify impact local control irradiate metastatic focus context systemic disease , local control affect disease free survival overall survival , moreover quality life patient treat .</detailed_description>
	<criteria>Age ≥18 year WHO performance status ≤ 2 Histologicallyproven primary cancer disease M1 stage primary cancer site radically treat complete response/resection stable . No site disease progression ( maximum 3 lymph node sit disease treat ) Diameter ≤ 5 cm Abdomen/pelvic site Informed consent . Patients require brain metastasis bone metastasis . Patients life expectancy &gt; 3 month . Any serious disease contraindicate radiation therapy Other coexist malignancy , uncontrolled intercurrent illness , active infectious process , exudative , bloody , cytologically malignant effusion exclude patient trial . Additionally , patient exclude trial receive systemic chemotherapy radiotherapy , although hormonal therapy allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>